Skip to main content
QURE
NASDAQ Life Sciences

uniQure to Submit BLA for Huntington's Disease Gene Therapy AMT-130 in Q3 2026 After Positive FDA Meeting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$27.5
Mkt Cap
$1.688B
52W Low
$8.73
52W High
$71.5
52W Position info
215% above low
Off High info
62% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73 on light trading volume (0.4× avg).

Summary

uniQure plans to submit a Biologic License Application (BLA) for its Huntington's disease gene therapy, AMT-130, in Q3 2026, following FDA agreement that Phase I/II data can support accelerated approval.


Key Events · Product Development and Regulatory · QURE

  • BLA Submission Plan for AMT-130

    uniQure N.V. announced its plan to submit a Biologic License Application (BLA) for AMT-130 in Huntington's Disease during the third quarter of 2026.

  • FDA Accepts Phase I/II Data for Accelerated Approval Basis

    The FDA communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis for accelerated approval of AMT-130.

  • Confirmatory Study Design Alignment Required

    Prior to BLA submission, the FDA seeks alignment on the confirmatory study design, including consideration of a concurrent control of standard of care without a sham procedure.

  • Existing Regulatory Designations

    AMT-130 has previously been granted Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy, and Fast Track designations by the FDA.


Analysis · QURE · Life Sciences

This is a critical positive development for uniQure's lead gene therapy candidate, AMT-130, for Huntington's Disease. The FDA's agreement to accept Phase I/II study data as the primary basis for an accelerated approval Biologic License Application (BLA) significantly de-risks the regulatory pathway and accelerates the potential timeline to market. While alignment on a confirmatory study design is still needed, this is a standard requirement for accelerated approvals and the FDA has committed to working expeditiously. This news provides a strong counter-signal to recent negative events, including a securities fraud lawsuit and an FDA setback for another candidate (AMT-191).

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $23.81 info
Change: +$1.21 (+5%) info
Market Cap: $1.67B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $23.81 info
Change: +$1.37 (+6%) info
Market Cap: $1.67B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $23.81 info
Change: -$3.85 (-14%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $23.81 info
Change: +$1.81 (+8%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $23.81 info
Change: +$1.61 (+7%) info
Market Cap: $1.67B info